Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...

Travis County Judge Jessica Mangrum granted a temporary restraining order halting Robert Roberson's execution at the request ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target ...

Abbott Laboratories ABT reported better-than-expected third-quarter results on Wednesday. The company posted sales of $10.64 ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

The Searle Company Limited (PSX: SEARL) has denied showing any interest in acquiring a 51 percent stake in Abbott ...

Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...